| Protein Name: | Adenylate kinase (P00568) |
|---|---|
| Gene Name: | AK1 |
| Description: | Adenylate kinase isoenzyme 1 (EC 2 7 4 3) (ATP-AMP transphosphorylase) (AK1) (Myokinase) |
| PDB ID: | 1Z83 |
| Protein Family: | |
| Protein Category: | Enzyme |
This panel provides drug-protein interaction and their ADRs along with references
| Interacting Drugs | Toxicity | Mechanism | Reference |
|---|---|---|---|
| Aminoglutethimide | Cardiovascular Disease | Total suppression of aromatase by Cytadren may have adverse effects of cardiovascular disease [ ADR Type 1 ] | Aromatase inhibitors as potential cancer chemopreventives |
| Aminoglutethimide | Osteoporosis | Total suppression of aromatase by Cytadren may have adverse effects of increased osteoporosis. [ ADR Type 1 ] | Aromatase inhibitors as potential cancer chemopreventives |
| Aminoglutethimide | Urogenital Atrophy | Total suppression of aromatase by Cytadren may have adverse effects of urogenital atrophy [ ADR Type 1 ] | Aromatase inhibitors as potential cancer chemopreventives |
| Anastrozole | Cardiovascular Disease | Total suppression of aromatase by Arimidex may have adverse effects of cardiovascular disease. [ ADR Type 1 ] | Aromatase inhibitors as potential cancer chemopreventives |
| Anastrozole | Osteoporosis | Total suppression of aromatase by Arimidex may have adverse effects of increased osteoporosis. [ ADR Type 1 ] | Aromatase inhibitors as potential cancer chemopreventives |
| Anastrozole | Urogenital Atrophy | Total suppression of aromatase by Arimidex may have adverse effects of urogenital atrophy [ ADR Type 1 ] | Aromatase inhibitors as potential cancer chemopreventives |
| Atamestane | Cardiovascular Disease | Total suppression of aromatase by atamestane may have adverse effects of cardiovascular disease [ ADR Type 1 ] | Aromatase inhibitors as potential cancer chemopreventives |
| Atamestane | Osteoporosis | Total suppression of aromatase by atamestane may have adverse effects of increased osteoporosis [ ADR Type 1 ] | Aromatase inhibitors as potential cancer chemopreventives |
| Atamestane | Urogenital Atrophy | Total suppression of aromatase by atamestane may have adverse effects of urogenital atrophy [ ADR Type 1 ] | Aromatase inhibitors as potential cancer chemopreventives |
| Exemestane | Cardiovascular Disease | Total suppression of aromatase by exemestane may have adverse effects of cardiovascular disease [ ADR Type 1 ] | Aromatase inhibitors as potential cancer chemopreventives |
| Exemestane | Osteoporosis | Total suppression of aromatase by exemestane may have adverse effects of increased osteoporosis. [ ADR Type 1 ] | Aromatase inhibitors as potential cancer chemopreventives |
| Exemestane | Urogenital Atrophy | Total suppression of aromatase by exemestane may have adverse effects of urogenital atrophy [ ADR Type 1 ] | Aromatase inhibitors as potential cancer chemopreventives |
| Fadrozole hydrochloride | Cardiovascular Disease | Total suppression of aromatase by fadrozole hydrochloride may have adverse effects of cardiovascular disease [ ADR Type 1 ] | Aromatase inhibitors as potential cancer chemopreventives |
| Fadrozole hydrochloride | Osteoporosis | Total suppression of aromatase by fadrozole hydrochloride may have adverse effects of increased osteoporosis. [ ADR Type 1 ] | Aromatase inhibitors as potential cancer chemopreventives |
| Fadrozole hydrochloride | Urogenital Atrophy | Total suppression of aromatase by fadrozole hydrochloride may have adverse effects of urogenital atrophy. [ ADR Type 1 ] | Aromatase inhibitors as potential cancer chemopreventives |
| Formestane | Cardiovascular Disease | Total suppression of aromatase by formestane may have adverse effects of cardiovascular disease [ ADR Type 1 ] | Aromatase inhibitors as potential cancer chemopreventives |
| Formestane | Osteoporosis | Total suppression of aromatase by formestane may have adverse effects of increased osteoporosis [ ADR Type 1 ] | Aromatase inhibitors as potential cancer chemopreventives |
| Formestane | Urogenital Atrophy | Total suppression of aromatase by formestane may have adverse effects of urogenital atrophy. [ ADR Type 1 ] | Aromatase inhibitors as potential cancer chemopreventives |
| Letrozole | Cardiovascular Disease | Total suppression of aromatase by letrozole may have adverse effects of cardiovascular disease. [ ADR Type 1 ] | Aromatase inhibitors as potential cancer chemopreventives |
| Letrozole | Osteoporosis | Total suppression of aromatase by letrozole may have adverse effects of increased osteoporosis [ ADR Type 1 ] | Aromatase inhibitors as potential cancer chemopreventives |
| Letrozole | Urogenital Atrophy | Total suppression of aromatase by letrozole may have adverse effects of urogenital atrophy. [ ADR Type 1 ] | Aromatase inhibitors as potential cancer chemopreventives |
| Liarozole hydrochloride | Cardiovascular Disease | Total suppression of aromatase by liarozole hydrochloride may have adverse effects of cardiovascular disease. [ ADR Type 1 ] | Aromatase inhibitors as potential cancer chemopreventives |
| Liarozole hydrochloride | Osteoporosis | Total suppression of aromatase by liarozole hydrochloride may have adverse effects of increased osteoporosis [ ADR Type 1 ] | Aromatase inhibitors as potential cancer chemopreventives |
| Liarozole hydrochloride | Urogenital Atrophy | Total suppression of aromatase by liarozole hydrochloride may have adverse effects of urogenital atrophy [ ADR Type 1 ] | Aromatase inhibitors as potential cancer chemopreventives |
| rogletimide | Cardiovascular Disease | Total suppression of aromatase by rogletimide may have adverse effects of cardiovascular disease. [ ADR Type 1 ] | Aromatase inhibitors as potential cancer chemopreventives |
| rogletimide | Osteoporosis | Total suppression of aromatase by rogletimide may have adverse effects of increased osteoporosis [ ADR Type 1 ] | Aromatase inhibitors as potential cancer chemopreventives |
| rogletimide | Urogenital Atrophy | Total suppression of aromatase by rogletimide may have adverse effects of urogenital atrophy [ ADR Type 1 ] | Aromatase inhibitors as potential cancer chemopreventives |
| vorozole | Cardiovascular Disease | Total suppression of aromatase by vorozole may have adverse effects of cardiovascular disease. [ ADR Type 1 ] | Aromatase inhibitors as potential cancer chemopreventives |
| vorozole | Osteoporosis | Total suppression of aromatase by vorozole may have adverse effects of increased osteoporosis. [ ADR Type 1 ] | Aromatase inhibitors as potential cancer chemopreventives |
| vorozole | Urogenital Atrophy | Total suppression of aromatase by vorozole may have adverse effects of urogenital atrophy [ ADR Type 1 ] | Aromatase inhibitors as potential cancer chemopreventives |
This panel provides information on drug category
| Toxicity | Source |
|---|